What's new? Log in Free sign up

Greenwich LifeSciences (GLSI)

Company Profile

Company profile

Ticker

GLSI

Exchange

Website

greenwichlifesciences.com

CEO

Mr. Snehal S. Patel

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

205473709

GLSI stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Registration of securities for employees

Submission of Matters to a Vote of Security Holders

Quarterly report

14 Nov 24

Additional proxy soliciting materials

Annual report to shareholders

Definitive proxy

1 Nov 24

Notice of effectiveness

Shelf registration

Quarterly report

14 Aug 24

$2.50 mm in equity, sold $2.50 mm, 1 investor

Latest ownership filings

View all

Kenneth Hallock

Frank Joseph Daugherty

Financial summary

Financial statements Chart GLSI financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	5.82 mm	5.82 mm	5.82 mm	5.82 mm	5.82 mm	5.82 mm
Cash burn (monthly)	467.50 k	276.77 k	909.68 k	896.97 k	861.31 k	630.71 k
Cash used (since last report)	2.37 mm	1.40 mm	4.61 mm	4.54 mm	4.36 mm	3.19 mm
Cash remaining	3.45 mm	4.42 mm	1.22 mm	1.28 mm	1.46 mm	2.63 mm
Runway (months of cash)	7.4	16.0	1.3	1.4	1.7	4.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

GLSI institutional ownership history Ownership history

12.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	41	35	+17.1%
Opened positions	10	13	-23.1%
Closed positions	4	10	-60.0%
Increased positions	12	12	–
Reduced positions	8	4	+100.0%

13F shares	Current	Prev Q	Change
Total value	16.44 bn	17.49 bn	-6.0%
Total shares	1.59 mm	1.45 mm	+9.5%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Weiner Michael Guy	429.69 k	$9.35 mm	0.0%
BlackRock	350.14 k	$5.03 bn	NEW
Vanguard	273.52 k	$3.93 bn	+2.0%
Geode Capital Management	133.55 k	$1.92 bn	+4.6%
Credit Agricole S A	87.00 k	$1.25 bn	0.0%
NTRS Northern Trust	74.50 k	$1.07 bn	+206.3%
STT State Street	71.41 k	$1.03 bn	+4.4%
Renaissance Technologies	32.50 k	$467.03 mm	-11.9%
Garden State Investment Advisory Services	17.60 k	$252.91 mm	NEW
MS Morgan Stanley	17.03 k	$244.74 mm	+141.5%

Largest transactions	Shares	Bought/sold	Change
BlackRock	350.14 k	+350.14 k	NEW
BLK BlackRock	0.00	-308.91 k	EXIT
NTRS Northern Trust	74.50 k	+50.18 k	+206.3%
Garden State Investment Advisory Services	17.60 k	+17.60 k	NEW
Man Group Limited	0.00	-16.65 k	EXIT
Millennium Management	10.64 k	+10.64 k	NEW
MS Morgan Stanley	17.03 k	+9.98 k	+141.5%
STRS Ohio	12.80 k	+8.00 k	+166.7%
BCS Barclays	8.56 k	+6.54 k	+323.3%
Geode Capital Management	133.55 k	+5.86 k	+4.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

GLSI insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
10 Jan 25	Snehal Patel	Common Stock	Buy	Acquire P	No	No	12.51	2,500	31.28 k	5,552,502
7 Jan 25	Snehal Patel	Common Stock	Buy	Acquire P	No	No	13.75	1,800	24.75 k	5,550,002
6 Jan 25	Snehal Patel	Common Stock	Buy	Acquire P	No	No	13.31	1,100	14.64 k	5,548,202
3 Jan 25	Snehal Patel	Common Stock	Buy	Acquire P	No	No	12.95	3,400	44.03 k	5,547,102
2 Jan 25	Snehal Patel	Common Stock	Buy	Acquire P	No	No	11.97	2,000	23.94 k	5,543,702
31 Dec 24	Snehal Patel	Common Stock	Buy	Acquire P	No	No	11.36	2,400	27.26 k	5,541,702

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Greenwich LifeSciences, Maintains $38 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and maintains $38 price target.

Greenwich Lifesciences Announced The Following Update On FLAMINGO-01 Open Label HLA Data

Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 treated and placebo

Greenwich LifeSciences Reports Initiation Of New Clinical Sites In US

Both Harvard University and Johns Hopkins University sites were recently added as participating sites in FLAMINGO-01 in the US and both principal investigators, Laura Spring and Cesar Santa-Maria have joined the Steering

Greenwich Lifesciences Inks Partnership With GBG In Germany For Flamingo-01

Greenwich LifeSciences Announced The Activation Of Clinical Sites In France And Has Partnered With Unicancer For FLAMINGO-01 study Of GLSI-100, An Immunotherapy To Prevent Breast Cancer Recurrences

Press releases

From Benzinga Pro

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI)

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Greenwich LifeSciences, Inc. (NASDAQ:GLSI) on behalf of the company's shareholders. The investigation seeks to

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

STAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.